The myElanco Product Portfolio

Make use of the filters below to quickly find what you are looking for or browse our full portfolio of innovative products.

Search Resources


Displaying 0 of 0 Product(s)

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

Having any questions regarding our products?

Advantage Multi® for Cats

Indications

Advantage Multi for Cats is indicated for the prevention of heartworm disease caused by Dirofilaria immitisAdvantage Multi for Cats kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. Advantage Multi for Cats is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites:

Important Safety Information:

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

WARNINGS: Do not use on sick or debilitated cats or ferrets. Do not use on underweight cats. (see ADVERSE REACTIONS). 

Do not use on cats less than 9 weeks of age and cats or ferrets less than 2 lbs body weight.

PRECAUTIONS: Avoid oral ingestion.

HUMAN WARNINGS: Children should not come in contact with the application site for 30 minutes following application.


Advantage Multi® for Dogs

CAUTION: Federal (U.S.A.) law restricts Advantage Multi® for Dogs to use by or on the order of a licensed veterinarian.

WARNING: DO NOT ADMINISTER THIS PRODUCT ORALLY. For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. (See Contraindications, Warnings, Human Warnings, and Adverse Reactions for more information.)

PRECAUTIONS: Avoid oral ingestion.

CONTRAINDICATIONS: Do not use this product on cats.

HUMAN WARNINGS: Children should not come in contact with the application sites for two (2) hours after application.


Advantage® II for Cats

Side effects, although very rare, may include signs of skin irritation such as redness, scratching or other signs of discomfort. Gastrointestinal signs such as hypersalivation, vomiting or diarrhea have also been reported. Individual sensitivities, while rare, may occur after using ANY pesticide product for cats.

RESTRICTIONS: Use only on cats or kittens 8 weeks and older. Do not apply to cats or kittens weighing less than 2 lbs. Do not use on other animals. Do not apply more than 1 tube per treatment, even for large cats.

Hazards to humans: Harmful if swallowed. Causes moderate eye irritation. Avoid contact with eyes or clothing. Keep out of reach of children; do not have contact or allow children to have contact with treated area until completely dry. Do not contaminate feed or food.

For more information, please refer to the Product Label.


Advantage® II for Dogs

This fragrance-free topical is waterproof after 24 hours and is for use on dogs and puppies 7 weeks of age and older, weighing 3 lbs. or more.

Side effects, although very rare, may include signs of skin irritation such as redness, scratching or other signs of discomfort. Gastrointestinal signs such as vomiting, or diarrhea have also been reported.

Restrictions: Use only on dogs 7 weeks and older. Do not apply to puppies or dogs weighing less than 3 lbs. Do not use on other animals. Do not use on cats. Do not apply more than 1 tube per treatment. Do not have contact or allow children to have contact with treated area until completely dry.

For more information, please refer to the Product Label.


Atopica® for Cats

Indication
ATOPICA® for Cats (cyclosporine oral solution) USP MODIFIED is indicated for the control of feline allergic dermatitis as manifested by excoriations (including facial and neck), miliary dermatitis, eosinophilic plaques, and self-induced alopecia in cats at least 6 months of age and at least 3 lbs. in body weight.

Important Safety Information

Do not use in cats with a history or suspicion of malignant disorders, feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV) infection, or hypersensitivity to cyclosporine. Atopica is a systemic immunosuppressant that may increase susceptibility to infection, development of neoplasia, and decrease response to vaccination. Persistent, progressive weight loss may result in hepatic lipidosis; monitoring of body weight is recommended. For use only in cats. Wash hands after administration. People with known hypersensitivity should avoid contact with Atopica. Do not use with other immunosuppressive agents. It is important for cats to avoid exposure to Toxoplasma gondii during treatment. Use with caution in cats with diabetes mellitus or renal insufficiency, and with drugs that affect the P-450 enzyme system. The most common adverse events were vomiting, weight loss, diarrhea or loss of appetite. Please speak with your veterinarian for advice.


Atopica® for Dogs

Indication
ATOPICA is indicated for the control of atopic dermatitis in dogs weighing at least 4 pounds and at least 6 months of age.

Important Safety Information

Do not use Atopica in dogs with a history of neoplasia, with a hypersensitivity to cyclosporine, or in reproducing dogs. Atopica is a systemic immunosuppressant that may increase susceptibility to infection and development of neoplasia. For use only in dogs. Capsules should not be broken or opened. Wear gloves during administration and wash hands after administration. Gastrointestinal problems and gingival hyperplasia may occur at the initial dose.


Baytril® Antibacterial Injectable Solution for Dogs

INDICATIONS

Baytril® (brand of enrofloxacin) Injectable Solution is indicated for the management of diseases associated with bacteria susceptible to enrofloxacin.

CAUTION:

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

PRECAUTION:

Quinolone-class drugs should be used with caution in animals with

known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures.

Quinolone-class drugs have been associated with cartilage erosions in weight-bearing joints and other forms of arthropathy in immature animals of various species.

The use of fluoroquinolones in cats has been reported to adversely affect

the retina. Such products should be used with caution in cats.

ADVERSE REACTIONS:

No drug-related side effects were reported in 122 clinical cases treated with Baytril® (enrofloxacin) Injectable Solution followed by Baytril® Tablets at 5.0 mg/kg per day.


Baytril® Otic Emulsion for tough canine otitis externa

INDICATIONS:

Baytril® Otic is indicated as a treatment for canine otitis externa complicated by bacterial and funal organisms susceptible to enrofloxacin and/or silver sulfadiazine.

CAUTION:

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

PRECAUTIONS:

The safe use of Baytril® Otic in dogs used for breeding purposes, during pregnancy, or in lactating bitches has not been evaluated. The use of Baytril® Otic in dogs with perforated tympanic membranes has not been evaluated. Therefore, the integrity of the tympanic membrane should be evaluated before administering this product. If hearing or vestibular dysfunction is noted during the course of treatment, discontinue use of Baytril® Otic.

ADVERSE REACTIONS:

During clinical trials, dogs exhibited acute inflammation of the ear canal and pinna.


Baytril® (enrofloxacin) Antibacterial Tablets for Dogs, Cats

Baytril® (brand of enrofloxacin) Antibacterial Tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. Baytril® Antibacterial Tablets are indicated for use in dogs and cats.

CAUTION:

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

PRECAUTIONS:

Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures.

Quinolone-class drugs have been associated with cartilage erosions in weight-bearing joints and other forms of arthropathy in immature animals of various species.

The use of fluoroquinolones in cats has been reported to adversely affect the retina. Such products should be used with caution in cats.

ADVERSE REACTIONS:

Dogs: Two of the 270 (0.7%) dogs treated with Baytril® (brand of enrofloxacin) Tablets at 5.0 mg/kg per day in the clinical field studies exhibited side effects, which were apparently drug-related. These two cases of vomition were self-limiting.

Cats: No drug-related side effects were reported in 124 cats treated with Baytril® (brand of enrofloxacin) Tablets at 5.0 mg/kg per day for 10 days in clinical field studies.


Claro® Otic Solution

Indication

Claro® is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

Important Safety Information

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. PRECAUTIONS: For use in dogs only. Do not use in cats. (See POST-APPROVAL EXPERIENCE.) CLARO® has been associated with rupture of the tympanic membrane. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment. Signs of internal ear disease such as head tilt, vestibular signs, ataxia, nystagmus, facial paralysis, and keratoconjunctivitis sicca have been reported (see POST-APPROVAL EXPERIENCE) with the use of CLARO®. Wear eye protection when administering CLARO®. (See Human Warnings, PRECAUTIONS, POST-APPROVAL EXPERIENCE.)


Credelio® for Cats

Indications

Credelio CAT kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) for one month in cats and kittens 8 weeks of age and older and weighing 2.0 pounds or greater.

Credelio CAT is also indicated for treatment and control of Ixodes scapularis (black-legged tick) infestations for one month in cats and kittens 6 months of age and older and weighing 2.0 pounds or greater.

Important Safety Information

Lotilaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. The safety of Credelio CAT has not been established in breeding, pregnant and lactating cats. The effectiveness of Credelio CAT against Ixodes scapularis in kittens less than 6 months of age has not been evaluated. The most frequently reported adverse reactions are weight loss, tachypnea and vomiting. For full prescribing information see Credelio CAT package insert.


Credelio® for Dogs

Indications for Credelio

Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick) and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older and weighing 4.4 pounds or greater.  

Important Safety Information (ISI)

Lotilaner is a member of the isoxazoline class.  This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, polyuria, and diarrhea.  For full prescribing information see Credelio package insert.


Deramaxx®

Indications

DERAMAXX® Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis, orthopedic surgery or dental surgery in dogs.

Important Safety Information

Not for use in humans. For use in dogs only. Keep this and all medication out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Use with other NSAIDs or corticosteroids should be avoided. See accompanying safety summary for additional important safety information.


Elura® for Cats

INDICATION: Elura® is indicated for management of weight loss in cats with chronic kidney disease.

IMPORTANT SAFETY INFORMATION: For oral use in cats only. Do not use in cats that have a hypersensitivity to capromorelin or in cats with hypersomatotropism (acromegaly). Elura® may increase serum glucose for several hours after dosing; use in cats with current or historical diabetes mellitus has not been evaluated and may not be appropriate. Use with caution in cats that may have cardiac disease, severe dehydration or hepatic dysfunction. Elura® has not been evaluated in cats younger than 5 months of age or in breeding, pregnant or lactating cats. The most common adverse reactions included vomiting, hypersalivation, inappetence, behavior change and lethargy. Please see Elura® product label for full prescribing information.


Entyce® for Dogs

The effectiveness of Entyce® has not been studied beyond 4 days in the clinical study. 

INDICATION: For appetite stimulation in dogs.

IMPORTANT SAFETY INFORMATION: For use in dogs only. Do not use in dogs that have a hypersensitivity to capromorelin. Use with caution in dogs with hepatic dysfunction or renal insufficiency. The safe use of Entyce® has not been evaluated in breeding, pregnant or lactating dogs. The most common adverse reactions included diarrhea, vomiting, elevated blood urea nitrogen, polydipsia and hypersalivation.

Please see Entyce® product label for full prescribing information.


Galliprant®

Indication

Galliprant® is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.

Important Safety Information

Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant®. If Galliprant® is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant® with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant® has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.


Interceptor® Plus for Dogs

Indications for Interceptor® Plus

Interceptor® Plus is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of adult roundworm (Toxocara canis, Toxascaris leonina), adult hookworm (Ancylostoma caninum), adult whipworm (Trichuris vulpis), and adult tapeworm (Taenia pisiformis, Echinococcus multilocularis, Echinococcus granulosus and Dipylidium caninum) infections in dogs and puppies 6 weeks or older and 2 pounds or greater.

Important Safety Information

Treatment with fewer than 6 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to administration of Interceptor® Plus, dogs should be tested for existing heartworm infections. The safety of Interceptor® Plus has not been evaluated in dogs used for breeding or in lactating females. The following adverse reactions have been reported in dogs after administration of milbemycin oxime or praziquantel: vomiting, diarrhea, depression/lethargy, ataxia, anorexia, convulsions, weakness, and salivation. For full prescribing information see Interceptor® Plus package insert.


K9 Advantix® II for Dogs

It is a violation of Federal Law to use this product in a manner inconsistent with its labeling. Do not contaminate feed or food.

Restrictions:

  • Do not allow children to apply product.
  • Do not have contact or allow children to have contact with treated area until completely dry.
  • Do not apply an excessive amount of solution at any one spot that could cause some of the solution to run off the side of the dog.
  • Do not get this product in your dog’s eyes or allow your dog to ingest this product.
  • Dogs should be dry prior to application and remain dry for 24 hours after application for product to work effectively.
  • Do not use on cats. Keep cats away from treated dogs for 24 hours.

For further information, please refer to the Product Label


Nocita™ for Dogs and Cats

Indication

For single-dose infiltration into the surgical site to provide local postoperative analgesia for cranial cruciate ligament surgery in dogs. For use as a peripheral nerve block to provide regional postoperative analgesia following onychectomy in cats.

Important Safety Information

NOCITA™ is for use in dogs and cats only. Do not administer concurrently with bupivacaine HCl, lidocaine or other amide local anesthetics. The safe use of NOCITA™ in dogs and cats with cardiac disease or with hepatic or renal impairment has not been evaluated. The safe use in dogs or cats younger than 5 months of age, that are pregnant, lactating, or intended for breeding has not been evaluated. The most common adverse reactions in dogs were discharge from incision, incisional inflammation and vomiting. The most common adverse reactions in cats were elevated body temperature and infection or chewing/licking at the surgical site. Click here to view full product label.


Onsior® for Cats

Indications for Cats

ONSIOR® tablets for Cats are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration, in cats ≥ 5.5 lbs and ≥ 4 months of age; for up to a maximum of 3 days.

ONSIOR® injection is indicated for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration in cats ≥ 4 months of age; for up to a maximum of 3 days.

Important Safety Information for Cats

Do not use in cats that have hypersensitivity to robenacoxib or known intolerance to NSAIDs. Do not administer Onsior® tablets or injection in conjunction with any other NSAID or corticosteroid. Do not use for more than 3 days. A thorough history and physical exam including appropriate testing should be conducted before initiation of a NSAID therapy. Owners should be advised to observe for signs of potential drug toxicity. Stop administration of ONSIOR® if appetite decreases or if the cat becomes lethargic. The use of ONSIOR® has not been evaluated in cats used for breeding, or in pregnant or lactating cats or in cats with cardiac disease. As a class, cyclo-oxygenase inhibitory NSAIDS may be associated with gastrointestinal, renal, and hepatic toxicity. For full prescribing information see label links below.

ONSIOR® injection: For subcutaneous use in cats ≥ 4 months of age. Safety has not been demonstrated for intravenous or intramuscular administration. The most common adverse reactions were incision site infection, increased incision site bleeding, vomiting, inappetence and lethargy.

ONSIOR® tablets for Cats: For oral use in cats ≥ 5.5 lbs and ≥ 4 months of age only. The most common adverse events are anorexia, depression, vomiting, elevated BUN, elevated creatinine, and renal insufficiency/failure.


Profender® for Cats

Indications

PROFENDER Topical Solution is indicated for the treatment and control of hookworm infections caused by Ancylostoma tubaeforme (adults, immature adults, and fourth stage larvae), roundworm infections caused by Toxocara cati (adults and fourth stage larvae), and tapeworm infections caused by Dipylidium caninum (adults) and Taenia taeniaeformis (adults) in cats.

Important Safety Information:

CAUTION: Federal law (U.S.A.) restricts this drug to use by or on the order of a licensed veterinarian.

Topical Solution for the treatment and control of hookworm, roundworm and tapeworm infections in cats and kittens that are at least 8 weeks of age and weigh at least 2.2 lbs (1 kg).

HUMAN WARNINGS:

Not for human use. Keep out of reach of children.

To prevent accidental ingestion of the product, children should not come in contact with the application site for twenty-four (24) hours while the product is being absorbed. Pregnant women, or women who may become pregnant, should avoid direct contact with, or wear disposable gloves when applying, this product. Studies performed in rats and rabbits suggest that emodepside may interfere with fetal development in those species.

PROFENDER Topical Solution may be irritating to skin and eyes. Reactions such as facial, tongue and hand swelling have been reported in humans in rare instances. Avoid contact with the application area while it is wet and wash hands thoroughly with soap and warm water after handling. People with known hypersensitivity to butylhydroxyanisole, emodepside or praziquantel should administer the product with caution. If the product accidentally gets into eyes, flush thoroughly with water. May be harmful if swallowed. In case of accidental ingestion or if skin or eye irritation occurs, call a poison control center or physician for treatment advice.

The Safety Data Sheet (SDS) provides additional occupational safety information. For customer service or to obtain product information, including the SDS, call 1- 800-633-3796. For medical emergencies or to report an adverse reaction, call 1- 800-422-9874.


quellin®

CAUTION: Federal law restricts quellin® to use by or on the order of a licensed veterinarian.

WARNINGS: Keep quellin®  soft chew tablets out of reach of children. Not for human use. For use in dogs only. Do not use in cats. All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID should be considered.

PRECAUTIONS: Carprofen is an NSAID, and as with others in that class, adverse reactions may occur with its use. The most frequently reported effects have been gastrointestinal signs. Events involving suspected renal, hematologic, neurologic, dermatologic and hepatic effects have also been reported.

CONTRAINDICATIONS: Carprofen should not be used in dogs exhibiting previous hypersensitivity to carprofen.


Rabvac™

Always read, understand and follow the label and use directions.

Rabvac™ 1(50 Dose, 1 mL)

Rabvac™ 3(50 Dose, 1mL)


Seresto® for Cats

Scratching may be observed occasionally in cats that are not used to wearing collars during the first few days after fitting. Clients should ensure the collar is not fitted too tightly. Slight hair loss and mild skin reactions due to the mechanical irritation of the collar may occur at the application site; this usually clears within one or two weeks without the need for collar removal.

Do not open until ready to use. Keep out of reach of children; do not let children play with the collar or reflectors. Choking hazard; contains small parts.

For external use on cats only. Do not use on other animals. Not intended for use on humans.

For more information, please refer to the Product Label.


Seresto® for Dogs

Occasionally, scratching may be observed in dogs who are not used to wearing collars during the first few days after fitting. Clients should ensure the collar is not fitted too tightly. Slight hair loss and mild skin reactions due to the mechanical irritation of the collar may occur at the application site; this usually clears within one or two weeks without the need for collar removal.

Keep the collar in the bag and in the outer packaging until use. Keep out of reach of children. Choking hazard — contains small parts. For external use on dogs only. Do not use Seresto® for Dogs on other animals.

For more information, please refer to the Product Label.


Surolan®

Indication
SUROLAN® (miconazole nitrate, polymyxin B sulfate, prednisolone acetate) is indicated for the treatment of canine otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

Important Safety Information

Do not use Surolan® otic suspension in dogs with known perforated tympanum or with drugs known to induce ototoxicity. If overgrowth of non-susceptible bacteria or fungi occurs, treatment should be discontinued and appropriate therapy instituted. Long-term use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hypoadrenocorticism in dogs. The safe use of Surolan® in breeding animals has not been evaluated. Please see product insert for full prescribing information.


Tanovea® for Dogs

INDICATION: Tanovea® is indicated for the treatment of lymphoma in dogs.

IMPORTANT SAFETY INFORMATION: Tanovea® is not for use in humans.  Keep out of reach of children.  Do not come into direct contact with Tanovea®.  Wear chemotherapy-resistant gloves to prevent contact with feces, urine, vomit, and saliva of treated dogs for five days following treatment.  Rabacfosadine is cytotoxic and may cause birth defects and affect female and male fertility.  Pregnant women, those who may become pregnant, and nursing women should not handle, prepare or administer the product.  Tanovea® is associated with life-threatening or fatal pulmonary fibrosis.  Monitoring for signs of pulmonary dysfunction is recommended.  Do not use in dogs with pulmonary fibrosis, a history of chronic pulmonary disease that could lead to fibrosis, or in breeds with a predisposition to this condition such as West Highland White Terriers. Use with caution in other terrier breeds. Do not use in dogs that are pregnant, lactating, or intended for breeding.  Tanovea® is associated with dermatopathies which can worsen with subsequent treatment; careful monitoring is recommended.  Tanovea® can cause neutropenia with nadir around seven days post-treatment.  Dogs should be frequently monitored for evidence of neutropenia during treatment.  Most common adverse reactions included diarrhea, decreased appetite, emesis, lethargy, weight loss and neutropenia.

Please see Tanovea® product label for full Prescribing Information


Trifexis®

Indications

Trifexis® is indicated for the prevention of heartworm disease (Dirofilaria immitis). Trifexis® kills fleas and is indicated for the prevention and treatment of flea infestations (Ctenocephalides felis), and the treatment and control of adult hookworm (Ancylostoma caninum), adult roundworm (Toxocara canis and Toxascaris leonina) and adult whipworm (Trichuris vulpis) infections in dogs and puppies 8 weeks of age or older and 5 pounds of body weight or greater.

Important Safety Information (ISI)

Serious adverse reactions have been reported following concomitant extra-label use of ivermectin with spinosad alone, one of the components of Trifexis®. Treatment with fewer than three monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to administration of Trifexis®, dogs should be tested for existing heartworm infection. Use with caution in breeding females. The safe use of Trifexis® in breeding males has not been evaluated. Use with caution in dogs with pre-existing epilepsy. The most common adverse reactions reported are vomiting, depression/lethargy, pruritus, anorexia, and diarrhea. To ensure heartworm prevention, dogs should be observed for one hour after administration. If vomiting occurs within one hour of administration, redose. Puppies less than 14 weeks of age may experience a higher rate of vomiting. For full prescribing information see Trifexis® package insert.


TruCan™ Product Labels

http://www.elancolabels.com/us/trucan-bapi-in

http://www.elancolabels.com/us/trucan-b-oral

http://www.elancolabels.com/us/trucan-c

http://www.elancolabels.com/us/trucan-lyme

http://www.elancolabels.com/us/trucan-lyme-l4

http://www.elancolabels.com/us/trucan-dappi-lyme-l4

http://www.elancolabels.com/us/trucan-dappi-lyme-cl4

http://www.elancolabels.com/us/trucan-dappi

http://www.elancolabels.com/us/trucan-dappi+l4

http://www.elancolabels.com/us/trucan-dappi+cl4

http://www.elancolabels.com/us/trucan-dappi+c

http://www.elancolabels.com/us/trucan-pc

http://www.elancolabels.com/us/trucan-parvo

http://www.elancolabels.com/us/trucan-l4

http://www.elancolabels.com/us/trucan-ultra-l4

http://www.elancolabels.com/us/trucan-ultra-dap   

http://www.elancolabels.com/us/trucan-ultra-dap+l4

http://www.elancolabels.com/us/trucan-ultra-dap+c

http://www.elancolabels.com/us/trucan-ultra-dap+cl4

http://www.elancolabels.com/us/trucan-ultra-lyme


TruFel™ Product Labels

http://www.elancolabels.com/us/trufel-hcp-felv

http://www.elancolabels.com/us/trufel-hcp-ch

http://www.elancolabels.com/us/trufel-hcp-ch-felv

http://www.elancolabels.com/us/trufel-hc2pch

http://www.elancolabels.com/us/trufel-felv

http://www.elancolabels.com/us/trufel-hc2p-felv

http://www.elancolabels.com/us/trufel-hc2pch-felv

http://www.elancolabels.com/us/trufel-hc2p

http://www.elancolabels.com/us/trufel-hcp

http://www.elancolabels.com/us/trufel-ultra-felv

http://www.elancolabels.com/us/trufel-ultra-hc2p

http://www.elancolabels.com/us/trufel-ultra-hc2p-felv

http://www.elancolabels.com/us/ultra-hybrid-fvrcp


Veraflox® for Cats

INDICATION:

Veraflox® is indicated for the treatment of skin infections (wounds and abcesses) in cats caused by susceptible strains of Pasteurella multocida, Streptococcus canis, Staphylococcus aureus, Staphylococcus felis and Staphylococcus pseudintermedius.

CAUTION:

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals. For use in cats only.

PRECAUTIONS:
The use of fluoroquinolones in cats has been associated with the development of retinopathy and/or blindness. Such products should be used with caution in cats.


Zorbium™ for Cats

Indication

ZORBIUM™ is indicated for the control of postoperative pain associated with surgical procedures in cats.

Important Safety Information

Before using ZORBIUM™ (buprenorphine transdermal solution), read the entire package insert including the Boxed Human Warning.

ZORBIUM™ contains buprenorphine, an opioid that exposes humans to risks of misuse, abuse and addiction, which can lead to overdose and death. Use of buprenorphine may lead to physical dependence. The risk of abuse by humans should be considered when storing, administering and disposing of ZORBIUM™. Serious, life-threatening or fatal respiratory depression may occur with accidental exposure to or with misuse or abuse of ZORBIUM™. ZORBIUM™ should only be administered by veterinarians or veterinarian technicians who are trained in the handling of potent opioids. Accidental exposure to even one tube of ZORBIUM™, especially in children, can result in a fatal overdose.

ZORBIUM™ is for topical application in cats only. Do not come into direct contact with ZORBIUM™. Wear impermeable latex or nitrile gloves, protective glasses and a laboratory coat when applying ZORBIUM™. Following application to the cat, allow a minimum drying time of 30 minutes before direct contact with the application site. Do not administer to cats with a known hypersensitivity to buprenorphine hydrochloride, any inactive ingredients of ZORBIUM™, or known intolerance to opioids. Do not apply ZORBIUM™ if the application site at the dorsal cervical area has diseased or injured skin, or to anatomic areas other than the dorsal cervical area because absorption characteristics may be different. Body temperature should be monitored postoperatively. Most common adverse reactions during anesthesia were hypothermia, hypotension and hypertension, and after anesthetic recovery were hypothermia, hyperthermia and sedation. The safe use of ZORBIUM™ has not been evaluated in debilitated cats; those with renal, hepatic, cardiac or respiratory disease; pregnant, lactating or breeding cats; in cats younger than four months old; or in cats <2.6 lbs. or >16.5 lbs.

About Elanco

Learn why we're a leading provider of innovative solutions that protect and enhance animal health.

Connect with Elanco

PM-US-22-1298

© 2023 Elanco or its affiliates.